Issue link: https://nebusinessmedia.uberflip.com/i/781269
www.HartfordBusiness.com February 6, 2017 • Hartford Business Journal 9 To view the full list, please visit HartfordBusiness.com THE LIST venture capitalists in the state. Yet even before this stage, we need to tackle the funding gap that exists between the federally funded research projects and applied R&D activities. To make a technology attractive to inves- tors and partners, it is critical to have data to prove a concept. While there are a few federal pro- grams for applied R&D, they are highly competitive and can take quite some time to access. Our challenge is to move at a pace that keeps us ahead through easily accessible funding at this very early stage — sometimes even prior to company formation — that will allow us to attract investors and partners. Q: There are currently 35 companies located at TIP's two major locations in Storrs and at UConn Health in Farming- ton. What are the prospects for growth in these sites? A: Currently our TIP facility at Storrs is fully booked, but we expect some companies to grad- uate and make room for one or two new companies in the spring of 2017. The number of clients in Farmington has increased quick- ly since the state invested $19 million through Bioscience Con- necticut to expand the facility in Jan. 2016, and we anticipate high- quality companies from UConn, Connecticut, and beyond will fill the remaining space soon. n Q&A: Analoui UConn Health also just signed a genetics professor, doctor and National Academy of Sciences member in a co-recruitment with JAX, Liang said, adding that more talent continues to be sought. "I think it's going to be transformative," Liang said of the impact on the region, calling the recruitment a team effort and crediting the state's investment in bioscience for creating such high-level interest. The state legislature, led by Gov. Dannel P Malloy, committed $864 million to the industry in 2011 and $291 million in forgivable loans and grants to build JAX's Farmington facility. Yu-Hui Rogers, site director for The Jackson Labora- tory and JAX's second hire in Farmington in 2012, said the state's long-term commitment to bioscience and JAX's commitment to being a world-class research organization pursuing personalized genomic medicine are big draws. Also, JAX has high expectations for the people it seeks, which, in turn, attracts like-minded talent, she said. "We are really quite picky about who we actually invite to the party," Rogers said. "So we really are target- ing some of the most top-notch scientists and investiga- tors around the world." JAX has about 270 people in Farmington, including roughly 100 senior scientists with MD or Ph.D. degrees and 25 technical faculty, including three joint faculty with UConn Health, a number that will grow, she said. Hiring is running ahead of JAX's schedule to add 300 people within 10 years. It opened its building in fall 2014 and plans a second building, for which no dates have been announced. In the meantime, the region continues building its bioscience reputation. One opportunity includes microbiome research, for which JAX has attracted top researchers as it starts a microbiome initiative. JAX recently hired Mark Adams, whom Rogers called a pioneer in areas of genomics sequencing and microbial genomics, as director of microbial genomic services to enhance JAX's large-scale microbiome initiatives. n Bioscience Push Largest bioscience/biotechnology companies in Connecticut (Ranked by number of employees as of January 2017) Rank Company Headquarters No. of employees in CT Bioscience sub categories Focus Year founded Top executive 1 Pfizer Inc. 558 Eastern Point Road Groton, CT 06340 860-441-4100; www.pfizer.com New York, NY 3,000 Pharmaceuticals Medicinal chemistry, pharmacokinetics, dynamics and metabolism, pharmaceutical sciences, clinical trials, drug safety, comparative medicine, regulatory 1849 Ian C. Read Chairman & CEO 2 Boehringer Ingelheim Pharmaceuticals Inc. 900 Ridgebury Road Ridgefield, CT 06877 800-344-3095; us.boehringer-ingelheim.com Ridgefield, CT 2,456 (1) Pharmaceuticals Development and manufacture of human and animal healthcare products 1885 Paul R. Fonteyne President & CEO, USA 3 Alexion Pharmaceuticals Inc. 100 College St. New Haven, CT 06510 475-230-2596; alexion.com New Haven, CT 1,100 Pharmaceuticals Severe and life-threatening rare disorders 1992 David Brennan (2) Interim CEO 4 Bristol-Myers Squibb Co. 5 Research Parkway Wallingford, CT 06492 203-677-6000; www.bms.com New York, NY 700 (3) Bio-manufacturing Genetics Pharmaceuticals BioPharma focused on discovering, developing and delivering medicines to help patients prevail over serious diseases such as cancer, cardiovascular disease, fibrotic diseases, genetically defined diseases, hepatitis C, HIV and rheumatoid arthritis 1858 Giovanni Caforio CEO 5 PerkinElmer Inc. 710 Bridgeport Ave. Shelton, CT 06484 (4) 203-925-4600; www.perkinelmer.com Waltham, MA 500 Medical Agriculture Ecology R&D Chemical engineering Genetics Pharmaceuticals Forensic Science Detection, imaging, informatics and service capabilities related to human and environmental health 1937 Robert F. Friel Chairman & CEO 6 The Jackson Laboratory for Genomic Medicine (5) 10 Discovery Drive Farmington, CT 06032 860-837-2474; www.jax.org Bar Harbor, ME 257 Medical R&D Genetics Discovery of genomic causes of disease and development of diagnostics and therapeutics 2014 (6) Charles Lee Scientific director 7 MannKind Corp. 1 Casper St. Danbury, CT 06810 203-798-8000; www.mannkindcorp.com Valencia, CA 117 Pharmaceuticals Inhalation product technologies 1991 Matthew J. Pfeffer CEO, CFO & director 8 Scapa Healthcare 111 Great Pond Drive Windsor, CT 06095 860-688-8000; www.scapahealthcare.com Manchester, UK 100 Medical Bio-manufacturing Adhesive coated materials for the medical device, consumer wellness, advanced wound care and drug delivery fixation markets 1982 Joseph Davin President of health care 9 Protein Sciences Corp. 1000 Research Parkway Meriden, CT 06450 203-686-0800; www.proteinsciences.com Meriden, CT 88 Bio-engineering Pharmaceuticals Vaccine development and protein production 1983 Manon M. J. Cox President & CEO 10 Achillion Pharmaceuticals 300 George St. New Haven, CT 06511 203-624-7000; www.achillion.com New Haven, CT 80 Pharmaceuticals Therapy for chronic hepatitis C and a platform of specific complement factor D inhibitors 2000 Milind S. Deshpande President & CEO 11 Core Informatics 36 E. Industrial Road, 2nd floor Branford, CT 06405 866-823-0337; www.coreinformatics.com Branford, CT 70 Bio-informatics Data management and lab informatics solutions built on the platform for science 2005 Josh Geballe CEO 12 Transgenomic Inc. (7) 5 Science Park New Haven, CT 06511 203-907-2201; www.transgenomic.com Omaha, NE 55 Genetics Genetic testing 1997 Paul Kinnon President & CEO 13 Arvinas Inc. 5 Science Park New Haven, CT 06511 203-535-1456; www.arvinas.com New Haven, CT 42 Medical Development of therapeutics to treat a variety of diseases including cancer, pro-inflammatory, autoimmune and rare disease 2013 Manuel Litchman President & CEO 13 Ce3 Inc. 246 Goose Lane, Suite 202 Guilford, CT 06437 203-404-7500; www.ce3inc.com Guilford, Clinton CT 42 R&D Pharmaceuticals Contract research focused on providing biotechnology companies with phase 1 and 2 clinical trial execution and regulatory submission services 2005 Holly Ohanesian Coulter President & CEO 15 Melinta Therapeutics Inc. (7) 300 George St., Suite 301 New Haven, CT 06511 203-624-5606; www.melinta.com Lincolnshire, IL 40 Pharmaceuticals Discovery, development and commercialization of antibiotics to overcome resistant, life-threatening infections 2000 Eugene Sun CEO 16 CARA Therapeutics (8) 107 Elm St., 9th Floor & 4 Stamford Plaza Stamford, CT 06902 203-406-3703; www.caratherapeutics.com Stamford, CT 36 Medical Development of therapeutics to treat human diseases associated with pain, inflammation and pruritus 2004 Derek Chalmers Director, president & CEO 17 NanoViricides Inc. 1 Controls Drive Shelton, CT 06484 203-937-6137; www.nanoviricides.com Shelton, CT 30 Pharmaceuticals Nanotechnology-based biomimetic anti-viral medicines targeting influenzas, bird flu, HIV/AIDS, cold sores, genital herpes infection, viral eye diseases, ebola and dengue viruses 2005 Eugene Seymour, CEO Anil R. Diwan President & chairman 18 Celldex Therapeutics Inc. (9) 688 East Main St., Suite 1A Branford, CT 06405 203-483-3500; celldex.com Hampton, NJ 29 R&D Pharmaceuticals Immunotherapy, therapeutic antibodies, antibody drug conjugates, immune system modulators 2005 Anthony Marucci President & CEO Source: CURE, each company via survey. Notes: R&D = research and development, DND = did not disclose. Hologic Inc., Medtronic and New Haven Pharmaceuticals do not disclose employee data by geographic location. AxioMx Inc. (Abcam plc), Becton Dickinson, Charles River Laboratories International Inc., CooperSurgical Inc., Gilead Connecticut Inc., Icahn School of Medicine Mount Sinai Genomics Research Center and Idexx Laboratories were contacted but did not complete a survey. Stamford's Purdue Pharma LP last responded to the survey in 2015, reporting 500 employees in CT. (1) 244 Connecticut employees were laid off in 2016. (2) Took over as interim CEO in Dec. 2016 upon the resignation of David L. Hallal. (3) In Dec. 2016, BMS announced previous plans to close Wallingford site by the end of 2018 are still in play, but the Connecticut development site that was to be built is no longer on the drawing board. (4) With an additional R&D operation in Branford. (5) Nonprofit residing on the campus of University of Connecticut Health Center. (6) Year founded for the Farmington site. The Jackson Laboratory was founded in 1929. (7) Data are from 2016 survey. (8) Relocated from Shelton to Stamford. (9) New Haven's Kolltan Pharmaceuticals Inc. was acquired by Celldex Therapeutics on Nov. 29, 2016. —Compiled by Stephanie R. Meagher. 2 900 Ridgebury Road Ridgefield, CT 06877 800-344-3095; us.boehringer-ingelheim.com Ridgefield, CT 2,456 (1) Pharmaceuticals Development and manufacture of human and animal healthcare products 1885 President & CEO, USA 3 Alexion Pharmaceuticals Inc. 100 College St. New Haven, CT 06510 475-230-2596; alexion.com New Haven, CT 1,100 Pharmaceuticals Severe and life-threatening rare disorders 1992 David Brennan (2) Interim CEO 4 Bristol-Myers Squibb Co. 5 Research Parkway Wallingford, CT 06492 203-677-6000; www.bms.com New York, NY 700 (3) Bio-manufacturing Genetics Pharmaceuticals BioPharma focused on discovering, developing and delivering medicines to help patients prevail over serious diseases such as cancer, cardiovascular disease, fibrotic diseases, genetically defined diseases, hepatitis C, HIV and rheumatoid arthritis 1858 Giovanni Caforio CEO 5 PerkinElmer Inc. 710 Bridgeport Ave. Shelton, CT 06484 (4) 203-925-4600; www.perkinelmer.com Waltham, MA 500 Medical Agriculture Ecology R&D Chemical engineering Genetics Pharmaceuticals Forensic Science Detection, imaging, informatics and service capabilities related to human and environmental health 1937 Robert F. Friel Chairman & CEO 6 The Jackson Laboratory for Genomic Medicine (5) 10 Discovery Drive Farmington, CT 06032 860-837-2474; www.jax.org Bar Harbor, ME 257 Medical R&D Genetics Discovery of genomic causes of disease and development of diagnostics and therapeutics 2014 (6) Charles Lee Scientific director 7 MannKind Corp. 1 Casper St. Danbury, CT 06810 203-798-8000; www.mannkindcorp.com Valencia, CA 117 Pharmaceuticals Inhalation product technologies 1991 Matthew J. Pfeffer CEO, CFO & director 8 Scapa Healthcare 111 Great Pond Drive Windsor, CT 06095 860-688-8000; www.scapahealthcare.com Manchester, UK 100 Medical Bio-manufacturing Adhesive coated materials for the medical device, consumer wellness, advanced wound care and drug delivery fixation markets 1982 Joseph Davin President of health care 9 Protein Sciences Corp. 1000 Research Parkway Meriden, CT 06450 203-686-0800; www.proteinsciences.com Meriden, CT 88 Bio-engineering Pharmaceuticals Vaccine development and protein production 1983 Manon M. J. Cox President & CEO 10 Achillion Pharmaceuticals 300 George St. New Haven, CT 06511 203-624-7000; www.achillion.com New Haven, CT 80 Pharmaceuticals Therapy for chronic hepatitis C and a platform of specific complement factor D inhibitors 2000 Milind S. Deshpande President & CEO 11 Core Informatics 36 E. Industrial Road, 2nd floor Branford, CT 06405 866-823-0337; www.coreinformatics.com Branford, CT 70 Bio-informatics Data management and lab informatics solutions built on the platform for science 2005 Josh Geballe CEO 12 Transgenomic Inc. (7) 5 Science Park New Haven, CT 06511 203-907-2201; www.transgenomic.com Omaha, NE 55 Genetics Genetic testing 1997 Paul Kinnon President & CEO 13 Arvinas Inc. 5 Science Park New Haven, CT 06511 203-535-1456; www.arvinas.com New Haven, CT 42 Medical Development of therapeutics to treat a variety of diseases including cancer, pro-inflammatory, autoimmune and rare disease 2013 Manuel Litchman President & CEO 13 Ce3 Inc. 246 Goose Lane, Suite 202 Guilford, CT 06437 203-404-7500; www.ce3inc.com Guilford, Clinton CT 42 R&D Pharmaceuticals Contract research focused on providing biotechnology companies with phase 1 and 2 clinical trial execution and regulatory submission services 2005 Holly Ohanesian Coulter President & CEO 15 Melinta Therapeutics Inc. (7) 300 George St., Suite 301 New Haven, CT 06511 203-624-5606; www.melinta.com Lincolnshire, IL 40 Pharmaceuticals Discovery, development and commercialization of antibiotics to overcome resistant, life-threatening infections 2000 Eugene Sun CEO 16 CARA Therapeutics (8) 107 Elm St., 9th Floor & 4 Stamford Plaza Stamford, CT 06902 203-406-3703; www.caratherapeutics.com Stamford, CT 36 Medical Development of therapeutics to treat human diseases associated with pain, inflammation and pruritus 2004 Derek Chalmers Director, president & CEO 17 NanoViricides Inc. 1 Controls Drive Shelton, CT 06484 203-937-6137; www.nanoviricides.com Shelton, CT 30 Pharmaceuticals Nanotechnology-based biomimetic anti-viral medicines targeting influenzas, bird flu, HIV/AIDS, cold sores, genital herpes infection, viral eye diseases, ebola and dengue viruses 2005 Eugene Seymour, CEO Anil R. Diwan President & chairman 18 Celldex Therapeutics Inc. (9) 688 East Main St., Suite 1A Branford, CT 06405 203-483-3500; celldex.com Hampton, NJ 29 R&D Pharmaceuticals Immunotherapy, therapeutic antibodies, antibody drug conjugates, immune system modulators 2005 Anthony Marucci President & CEO Source: CURE, each company via survey. Notes: R&D = research and development, DND = did not disclose. Hologic Inc., Medtronic and New Haven Pharmaceuticals do not disclose employee data by geographic location. AxioMx Inc. (Abcam plc), Becton Dickinson, Charles River Laboratories International Inc., CooperSurgical Inc., Gilead Connecticut Inc., Icahn School of Medicine Mount Sinai Genomics Research Center and Idexx Laboratories were contacted but did not complete a survey. Stamford's Purdue Pharma LP last responded to the survey in 2015, reporting 500 employees in CT. (1) 244 Connecticut employees were laid off in 2016. (2) Took over as interim CEO in Dec. 2016 upon the resignation of David L. Hallal. (3) In Dec. 2016, BMS announced previous plans to close Wallingford site by the end of 2018 are still in play, but the Connecticut development site that was to be built is no longer on the drawing board. (4) With an additional R&D operation in Branford. (5) Nonprofit residing on the campus of University of Connecticut Health Center. (6) Year founded for the Farmington site. The Jackson Laboratory was founded in 1929. (7) Data are from 2016 survey. (8) Relocated from Shelton to Stamford. (9) New Haven's Kolltan Pharmaceuticals Inc. was acquired by Celldex Therapeutics on Nov. 29, 2016. —Compiled by Stephanie R. Meagher. 2 Ridgefield, CT 06877 800-344-3095; us.boehringer-ingelheim.com USA 3 Alexion Pharmaceuticals Inc. 100 College St. New Haven, CT 06510 475-230-2596; alexion.com New Haven, CT 1,100 Pharmaceuticals Severe and life-threatening rare disorders 1992 David Brennan (2) Interim CEO 4 Bristol-Myers Squibb Co. 5 Research Parkway Wallingford, CT 06492 203-677-6000; www.bms.com New York, NY 700 (3) Bio-manufacturing Genetics Pharmaceuticals BioPharma focused on discovering, developing and delivering medicines to help patients prevail over serious diseases such as cancer, cardiovascular disease, fibrotic diseases, genetically defined diseases, hepatitis C, HIV and rheumatoid arthritis 1858 Giovanni Caforio CEO 5 PerkinElmer Inc. 710 Bridgeport Ave. Shelton, CT 06484 (4) 203-925-4600; www.perkinelmer.com Waltham, MA 500 Medical Agriculture Ecology R&D Chemical engineering Genetics Pharmaceuticals Forensic Science Detection, imaging, informatics and service capabilities related to human and environmental health 1937 Robert F. Friel Chairman & CEO 6 The Jackson Laboratory for Genomic Medicine (5) 10 Discovery Drive Farmington, CT 06032 860-837-2474; www.jax.org Bar Harbor, ME 257 Medical R&D Genetics Discovery of genomic causes of disease and development of diagnostics and therapeutics 2014 (6) Charles Lee Scientific director 7 MannKind Corp. 1 Casper St. Danbury, CT 06810 203-798-8000; www.mannkindcorp.com Valencia, CA 117 Pharmaceuticals Inhalation product technologies 1991 Matthew J. Pfeffer CEO, CFO & director 8 Scapa Healthcare 111 Great Pond Drive Windsor, CT 06095 860-688-8000; www.scapahealthcare.com Manchester, UK 100 Medical Bio-manufacturing Adhesive coated materials for the medical device, consumer wellness, advanced wound care and drug delivery fixation markets 1982 Joseph Davin President of health care 9 Protein Sciences Corp. 1000 Research Parkway Meriden, CT 06450 203-686-0800; www.proteinsciences.com Meriden, CT 88 Bio-engineering Pharmaceuticals Vaccine development and protein production 1983 Manon M. J. Cox President & CEO 10 Achillion Pharmaceuticals 300 George St. New Haven, CT 06511 203-624-7000; www.achillion.com New Haven, CT 80 Pharmaceuticals Therapy for chronic hepatitis C and a platform of specific complement factor D inhibitors 2000 Milind S. Deshpande President & CEO 11 Core Informatics 36 E. Industrial Road, 2nd floor Branford, CT 06405 866-823-0337; www.coreinformatics.com Branford, CT 70 Bio-informatics Data management and lab informatics solutions built on the platform for science 2005 Josh Geballe CEO 12 Transgenomic Inc. (7) 5 Science Park New Haven, CT 06511 203-907-2201; www.transgenomic.com Omaha, NE 55 Genetics Genetic testing 1997 Paul Kinnon President & CEO 13 Arvinas Inc. 5 Science Park New Haven, CT 06511 203-535-1456; www.arvinas.com New Haven, CT 42 Medical Development of therapeutics to treat a variety of diseases including cancer, pro-inflammatory, autoimmune and rare disease 2013 Manuel Litchman President & CEO 13 Ce3 Inc. 246 Goose Lane, Suite 202 Guilford, CT 06437 203-404-7500; www.ce3inc.com Guilford, Clinton CT 42 R&D Pharmaceuticals Contract research focused on providing biotechnology companies with phase 1 and 2 clinical trial execution and regulatory submission services 2005 Holly Ohanesian Coulter President & CEO 15 Melinta Therapeutics Inc. (7) 300 George St., Suite 301 New Haven, CT 06511 203-624-5606; www.melinta.com Lincolnshire, IL 40 Pharmaceuticals Discovery, development and commercialization of antibiotics to overcome resistant, life-threatening infections 2000 Eugene Sun CEO 16 CARA Therapeutics (8) 107 Elm St., 9th Floor & 4 Stamford Plaza Stamford, CT 06902 203-406-3703; www.caratherapeutics.com Stamford, CT 36 Medical Development of therapeutics to treat human diseases associated with pain, inflammation and pruritus 2004 Derek Chalmers Director, president & CEO 17 NanoViricides Inc. 1 Controls Drive Shelton, CT 06484 203-937-6137; www.nanoviricides.com Shelton, CT 30 Pharmaceuticals Nanotechnology-based biomimetic anti-viral medicines targeting influenzas, bird flu, HIV/AIDS, cold sores, genital herpes infection, viral eye diseases, ebola and dengue viruses 2005 Eugene Seymour, CEO Anil R. Diwan President & chairman 18 Celldex Therapeutics Inc. (9) 688 East Main St., Suite 1A Branford, CT 06405 203-483-3500; celldex.com Hampton, NJ 29 R&D Pharmaceuticals Immunotherapy, therapeutic antibodies, antibody drug conjugates, immune system modulators 2005 Anthony Marucci President & CEO Source: CURE, each company via survey. Notes: R&D = research and development, DND = did not disclose. Hologic Inc., Medtronic and New Haven Pharmaceuticals do not disclose employee data by geographic location. AxioMx Inc. (Abcam plc), Becton Dickinson, Charles River Laboratories International Inc., CooperSurgical Inc., Gilead Connecticut Inc., Icahn School of Medicine Mount Sinai Genomics Research Center and Idexx Laboratories were contacted but did not complete a survey. Stamford's Purdue Pharma LP last responded to the survey in 2015, reporting 500 employees in CT. (1) 244 Connecticut employees were laid off in 2016. (2) Took over as interim CEO in Dec. 2016 upon the resignation of David L. Hallal. (3) In Dec. 2016, BMS announced previous plans to close Wallingford site by the end of 2018 are still in play, but the Connecticut development site that was to be built is no longer on the drawing board. (4) With an additional R&D operation in Branford. (5) Nonprofit residing on the campus of University of Connecticut Health Center. (6) Year founded for the Farmington site. The Jackson Laboratory was founded in 1929. (7) Data are from 2016 survey. (8) Relocated from Shelton to Stamford. (9) New Haven's Kolltan Pharmaceuticals Inc. was acquired by Celldex Therapeutics on Nov. 29, 2016. —Compiled by Stephanie R. Meagher.